The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
Open accessThe DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Background and Objectives: The association between diabetes mellitus and increased risk of bone fractures has led to the investigation of the impact of antidiabetic drugs on bone metabolism. Glucagon-like peptide-1 receptor agonists (GLP1RAs) are a relatively novel and promising class of anti-hyperglycemic drugs. In addition to their blood glucose lowering action, GLP1RAs seem to have additional pleiotropic properties such as a beneficial skeletal effect; although the underlying mechanisms are not completely understood. The present systematic review summarizes current evidence about GLP1RAs and their effects on bone metabolism and fracture. Methods: An extensive literature search was conducted based on electronic databases namely, PubMed, Google Scholar and Cochrane Central Register of Controlled Trials (CENTRAL) through October 2019 to January 2020 for articles related to bone mineral density, diabetes mellitus and GLP1RAs. We included articles published in English. Finally, we included four randomized controlled trials, three meta-analyses, a case-control study and a population-based cohort analysis. Results: Based on the articles included, the animal studies indicated the salutary skeletal effects of GLP1RAs in opposition to what has been commonly observed in human studies, showing that these agents have no impact on bone mineral density (BMD) and the turnover markers. Moreover, it was demonstrated that GLP1 was not associated with fracture risk as compared to other anti-hyperglycemic drugs. Conclusions: Findings from this systematic review have demonstrated the neutral impact of GLP1RAs on BMD. Moreover, further double-blind randomized controlled trials are needed to draw more meaningful and significant conclusions on the efficacy of GLP1RAs on BMD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 RANKL is an osteoclast differentiation factor. This factor binds to the RANK receptor in primary osteoclast cells and leads to differentiation and activation of osteoclasts. RANK enhances the action of osteoclast while OPG binds to RANKL and therefore inhibits bone resorption. An imbalance of OPG/RANKL/RANK expression is responsible for osteoporosis [6] (Legend: IL: Interleukins, IFNγ: Interferon gamma, PTH: Parathormone, T4: Thyroxine, Vit D: Vitamin D, PDGF: Platelet-Derived Growth Factor, OPG: Osteoprotegerin, RANKL: Receptor activator of nuclear factor kappa-Β ligand, M-CSF: Macrophage colony stimulating factor. Blue arrows imply production; red arrows imply inhibition; green arrows imply stimulation) (T-Cell is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/T_cell#/media/File:Blausen_0625_Lymphocyte_T_cell_(crop).png. Bone cells are reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Bone#/media/File:604_Bone_cells.jpg. Vein is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Vein#/media/File:Vein_(retouched).svg. All images last accessed on 26 September 2020).](https://figures.cochat.ai/paper-figures/d25c5a316afd4b81b4723c3606a53765/the-impact-of-glp1-agonists-on-bone-metabolism-a-systematic-review-figure-1.jpg)
![Figure 2 The mechanism of GLP1 and GLP1A in bone formation: GLP1 or GLP1A bind to GLP1R. The complex activates PI3K and PKA, which subsequently phosphorylates (P) AKT, PKA as well as P38, ERK1/2 and JNK. AKT enters the nucleus and regulates gene transcription. In addition, PKA induces β-catenin, which also enters the nucleus through the Wnt/β-catenin pathway. Similarly, phosphorylated P38, JNK and ERK1/2 enter the nucleus. All transcription factors facilitate gene expression, which leads to the induction of bone formation (Legend: GLP1: Glucagon-like peptide 1, GLP1A: Glucagon-like peptide 1 agonist, GLP1R: Glucagon-like peptide 1 receptor, GS: G-Proteins, cAMP: cyclic AMP, PI3K: Phosphoinositide 3-kinases, PKA: Protein kinase A, P38: p38 mitogen-activated protein kinase, ERK1/2: extracellular signal-regulated kinases, JNK: c-Jun N-terminal kinase, RUNX2: Runt-related transcription factor 2, SP7: Transcription factor Sp7, OPN: Osteopontin, ALP: Alkaline phosphatase, OPG: Osteoprotegerin, BGLAP: Osteocalcin gene, COL1: Type-1 collagen. Reproduced from Xie et al. (2021) [9] under the Creative Common License CC BY 3.0 link: https://www.frontiersin.org/articles/10.3389/fphar.2021.697442/full, accessed on 28 January 2022).](https://figures.cochat.ai/paper-figures/2308e90b843d4ef79f29752983d3c3f3/the-impact-of-glp1-agonists-on-bone-metabolism-a-systematic-review-figure-2.jpg)
![Figure 3 The balance between osteoblast and osteoclast functions: GLP1 induces MSC differentiation to osteoblasts, through the MAPK pathway. Osteocytes, produce sclerostin, which is inhibited by GLP1. Normally, stimulated osteoblasts produce MCSF, RANKL and OPG, which stimulate osteoclast precursors in order to retain bone formation balance (i.e., osteoblast and osteoclast functions remain equilibrated). GLP1 induces MAPK and osteoblast function as well as inhibits osteoclast function through the calcitonin-dependent pathway (Legend: GLP1: Glucagon-like peptide 1, MSC: Mesenchymal Stem Cells, MAPK mitogen-activated protein kinase, MCSF: macrophage colony stimulating factor, RANKL: Receptor activator of nuclear factor kappa-Β ligand, OPG: Osteoprotegerin. Green arrows imply stimulation; red arrows imply inhibition; black arrows imply cellular stimulation) (Inspired and reproduced from Schiellerup et al. (2019) [21] under the Creative Common License CC BY 3.0, link: https://www.frontiersin.org/articles/10.3389/fendo.2019.00075/full, accessed on 28 January 2022. MSC is reproduced under CC BY 3.0 License from https://en.wikipedia.org/wiki/Mesenchymal_stem_cell, Osteoblast is reproduced under the CC BY 3.0 License from https://en.wikipedia.org/wiki/Osteoblast, Osteoclast is reproduced under the CC BY-SA 3.0 License from https://en.wikipedia.org/wiki/Osteoclast, Osteocytes are reproduced from https://en.wikipedia.org/wiki/Osteocyte. All images last accessed on 24 January 2022).](https://figures.cochat.ai/paper-figures/6ea76bf93f464fc2aad4fa4579117aa7/the-impact-of-glp1-agonists-on-bone-metabolism-a-systematic-review-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, pre-clinical studies suggest that GLP1Ra-based therapies may positively impact bone health by promoting bone formation and reducing bone turnover; yet, currently available clinical data on effects of GLP1Ras on human bone metabolism are largely neutral (i.e., no consistent changes are observed in bone turnover biomarkers, bone mineral density (BMD), or fracture risk (12)).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These limited findings align with pre-clinical data suggesting GLP1Ra-based therapies may positively impact bone health by promoting bone formation and reducing bone turnover (12, 44).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Interestingly, pre-clinical studies suggest that GLP1Ra-based therapies may positively impact bone health by promoting bone formation and reducing bone turnover; yet, currently available clinical data on effects of GLP1Ras on human bone metabolism are largely neutral (i.e., no consistent changes are observed in bone turnover biomarkers, bone mineral density (BMD), or fracture risk (12)).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [12]
In the citing paper
“therapies with second‐generation weight‐loss agents often result in a 2%–3% decrease in bone mass, increasing fracture risk [44]”
From Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (2025) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow
Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., et al. (2002) · Nature · doi:10.1038/nature00870 · Cited by 5,518 · cited 2×
“tion of those cells to adipocytes) [18].”
RetractedHADJIDAKIS, D. J., & ANDROULAKIS, I. I. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1365.035 · Cited by 1,360 · cited 1×
“Moreover, RANKL is bound by OPG, secreted by osteoblasts, which inhibits osteoclast differentiation [4,5] (Figure 1).”
BackgroundSystematic Review of Type 1 and Type 2 Diabetes Mellitus and Risk of Fracture
Janghorbani, M., Van Dam, R. M., Willett, W. C., & Hu, F. B. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm106 · Cited by 1,209 · cited 1×
“Patients with diabetes mellitus are at an increased risk of fragility fractures [1].”
BackgroundOsteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112 · cited 2×
“On the other hand, GLP1 has been found to reduce SOST (sclerostin) mRNA levels, which i known to inhi it bone formation through suppression of the Wnt/nt Wnt known to inhibit bone formation through suppression of tin mRNA and COL1 [15].”
BackgroundMechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Expression Profiling and Functional Analysis of Wnt Signaling Mechanisms in Mesenchymal Stem Cells
Etheridge, S. L., Spencer, G. J., Heath, D. J., & Genever, P. G. (2004) · STEM CELLS · doi:10.1634/stemcells.22-5-849 · Cited by 344 · cited 2×
“The canonical Wnt pathway, includes LPR5/6, β-catenin, GSK-3β and T cell factor activation which results in osteoblast differentiation and maturation [13,14].”
BackgroundThe Murine Glucagon-Like Peptide-1 Receptor Is Essential for Control of Bone Resorption
Yamada, C., Yamada, Y., Tsukiyama, K., Yamada, K., Udagawa, N., Takahashi, N., Tanaka, K., Drucker, D. J., Seino, Y., & Inagaki, N. (2008) · Endocrinology · doi:10.1210/en.2007-1292 · Cited by 318 · cited 3×
“Further on, GLP1 is able to decrease bone resorption through the calcitonin-dependent pathway [17].”
BackgroundInfluentialGlucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
Su, B., Sheng, H., Zhang, M., Bu, L., Yang, P., Li, L., Li, F., Sheng, C., Han, Y., Qu, S., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0361-4 · Cited by 203 · cited 2×
“Data revealed that liraglutide was associated with a decreased risk of fracture, while exenatide treatment was remarkably associated with an increased risk of fracture [41].”
BackgroundMa, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200 · cited 5×
“In particular, it has been found that GLP1 agonists are able to reduce serum levels of C-terminal cross-linked telopeptide of type I collagen (CTX-1) and uri ary deoxypyridinoline (DPD)/creatinine ratio [16], thus inhibiting osteoclast action.”
BackgroundResultInfluential
Cited by
Jensen, S. B. K., Sørensen, V., Sandsdal, R. M., Lehmann, E. W., Lundgren, J. R., Juhl, C. R., Janus, C., Ternhamar, T., Stallknecht, B. M., Holst, J. J., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.16775 · Cited by 155
Understanding the impact of diabetes on bone health: A clinical review
Sharma, P., Sharma, R., & Gaur, K. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100330 · Cited by 92
Tan, Y., Liu, S., & Tang, Q. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02468-5 · Cited by 75
“Contrastingly, a study by Daniilo-poulou et al. revealed no effect of GLP-1 receptor agonists on BMD and bone turnover markers in human studies, likely due to the small number of included studies and lack of quantitative analysis [43].”
Old, V. J., Davies, M. J., Papamargaritis, D., Choudhary, P., & Watson, E. L. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13677 · Cited by 55
Zhang, Y., Chen, G., Wang, W., Yang, D., Zhu, D., & Jing, Y. (2024) · Bone · doi:10.1016/j.bone.2024.117338 · Cited by 52
Metadata
- Authors
- Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N.
- Affiliations
- University of West Attica (GR)
- Choremeio Research Laboratory, First Department of Pediatrics, National and Kapodistrian University of Athens, Thivon & Levadeias 8, 11527 Athens, Greece
- Athens Naval & Veterans Hospital (GR)
- Corresponding author
- Vlachou, Eugenia
- Tsartsalis, Athanasios N.
- ORCID
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2022-02-02
- Volume
- 58
- Issue
- 2
- Pages
- 224
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- PMC
- PMC8878541
- OpenAlex
- W4210692687
- Cited by
- 74
- References
- 55
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 19 · 2023: 3 · 2022: 2
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicina (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- GLP-1 receptor agonists, bone metabolism, bone mineral density, fracture risk, diabetes mellitus, antidiabetic drugs, bone turnover markers, animal studies
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Case-Control Studies, Randomized Controlled Trials as Topic, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. https://app.cochat.ai/papers/10.3390/medicina58020224
- The paper
- Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022). The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. Medicina. https://doi.org/10.3390/medicina58020224
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.